about
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to addr...
Read More
24.09
-0.80
(-3.21%)
622.1K
XNAS Volume
XNAS 07 Apr, 2026 3:03 PM (EDT)
Not Eligible
Expensive Valuation
Technically Neutral
Immunovant Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..